Clinical Trials Using Ruxolitinib Phosphate

Clinical trials are research studies that involve people. The clinical trials on this list are studying Ruxolitinib Phosphate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-21 of 21
  • Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

    This randomized phase II trial studies how well ruxolitinib phosphate, and bosutnib, dasatinib, or nilotinib, work in treating patients with chronic myeloid leukemia. Chronic myeloid leukemia cells produce a protein called BCR-ABL. The BCR-ABL protein helps chronic myeloid leukemia cells to grow and divide. Tyrosine kinase inhibitors, such as bosutinib, dasatinib, and nilotinib, stop the BCR-ABL protein from working, which helps to reduce the amount of chronic myeloid leukemia cells in the body. Ruxolitinib is a different type of drug that helps to stop the body from making substances called growth factors. Chronic myeloid leukemia cells need growth factors to grow and divide. The addition of ruxolitinib to the tyrosine kinase inhibitor may or may not help reduce the amount of chronic myeloid leukemia cells in the body.
    Location: 504 locations

  • A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

    This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.
    Location: 34 locations

  • A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

    The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination of parsaclisib and ruxolitinib in subjects with myelofibrosis.
    Location: 22 locations

  • A Phase 2 / 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

    Phase 3 of this study is evaluating 200 mg BID of pacritinib compared to physician's choice (P / C) therapy in patients with MF and severe thrombocytopenia (platelet count <50,000 / μL). Approximately 180 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 120 patients) or to P / C therapy (approximately 60 patients) Phase 2 was an open-label, randomized, dose-ranging study designed to identify the most appropriate dosage of pacritinib for future studies based on risk / benefit profile. Patients were randomized 1:1:1 to three dosage arms: 100mg QD, 100mg BID or 200mg BID. A total of 164 patients were randomized in the phase 2 portion of Study PAC203, and 161 (98.2%) patients received any treatment with pacritinib. Condition or disease: Primary Myelofibrosis / Post-Polycythemia Vera Myelofibrosis / Post-essential Thrombocythemia Myelofibrosis Intervention / treatment: Drug-Pacritinib
    Location: 13 locations

  • Ruxolitinib Phosphate and Chemotherapy before Surgery in Treating Patients with Triple Negative Inflammatory Breast Cancer

    This phase II trial studies how well ruxolitinib phosphate and chemotherapy before surgery work in treating patients with triple negative inflammatory breast cancer. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, doxorubicin hydrochloride, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ruxolitinib phosphate, paclitaxel, and chemotherapy before surgery may kill more tumor cells.
    Location: 8 locations

  • A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

    This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.
    Location: 8 locations

  • Ruxolitinib Phosphate before and after Stem Cell Transplant in Treating Patients with Primary or Secondary Myelofibrosis

    This phase II trial studies how well ruxolitinib phosphate before and after stem cell transplant works in treating patients with primary or secondary myelofibrosis. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fludarabine and melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient’s immune cells and help destroy any remaining cancer cells.
    Location: 5 locations

  • Ruxolitinib Phosphate in Treating Older Patients with Acute Myeloid Leukemia in First Complete Remission after Donor Stem Cell Transplant

    This phase II trial studies how well ruxolitinib phosphate works in treating older patients with acute myeloid leukemia in first complete remission after donor stem cell transplant. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: 5 locations

  • Ruxolitinib and Tyrosine Kinase Inhibitors for the Treatment of Recurrent Chronic Phase-Chronic Myeloid Leukemia

    This phase II trial studies how well ruxolitinib and tyrosine kinase inhibitors (TKIs), including imatinib, dasatinib, nilotinib or bosutinib, work in treating patients who are attempting to stop TKI medications for a second time for chronic phase-chronic myeloid leukemia that has come back (recurrent). Ruxolitinib and imatinib, dasatinib, nilotinib or bosutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. The purpose of this trial is to see if adding ruxolitinib to imatinib, dasatinib, nilotinib or bosutinib works better in prolonging treatment-free remission in patients with chronic phase-chronic myeloid leukemia.
    Location: 3 locations

  • Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

    The purpose of this study is to evaluate the efficacy and safety of ruxolitinib versus anagrelide in subjects with essential thrombocythemia who are resistant to or intolerant of hydroxyurea.
    Location: 3 locations

  • Ruxolitinib, Decitabine, and Donor Lymphocyte Infusion in Treating Patients with Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome after Stem Cell Transplant

    This phase II trial studies how well ruxolitinib, decitabine, and donor white blood cells (donor lymphocyte infusion [DLI]) work in treating patients with acute myeloid leukemia or myelodysplastic syndrome that has come back after a stem cell transplant. Patients who have relapsed after a stem cell transplant commonly receive an infusion of immune cells from the original donor called a DLI. A DLI uses high dose chemotherapy prior to the infusion which increases the risk of graft versus host disease, a condition in which the transplanted cells attack the recipient’s body. While the cancer responds temporarily to high dose chemotherapy alone, it hasn’t been shown to bring about long-term remission. Instead of high dose chemotherapy, this study pairs DLI with decitabine, another chemotherapy drug, and adds ruxolitinib. Ruxolitinib is a type of drug called a "JAK" inhibitor and may help prevent graft-versus host disease. Giving ruxolitinib with decitabine and a DLI may decrease the risk of graft-versus host disease and increase the chances of remission.
    Location: 3 locations

  • Ruxolitinib in Treating Patients with Chronic Myelomonocytic Leukemia

    This phase II trial studies how well ruxolitinib works in treating patients with chronic myelomonocytic leukemia. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Ruxolitinib Phosphate in Treating Patients with Bronchiolitis Obliterans Syndrome after Donor Stem Cell Transplant

    This phase II trial studies how well ruxolitinib phosphate works in treating patients with bronchiolitis obliterans syndrome after donor stem cell transplant. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts

  • VSV-hIFNbeta-NIS with or without Ruxolitinib Phosphate in Treating Patients with Stage IV or Recurrent Endometrial Cancer

    This phase I trial studies the side effects and best dose of vesicular stomatitis virus-human interferon beta-sodium iodide symporter (VSV-hIFNbeta-NIS) with or without ruxolitinib phosphate in treating patients with stage IV endometrial cancer or endometrial cancer that has come back. The study virus, VSV-hIFNbeta-NIS, has been changed so that it has restricted ability to spread to tumor cells and not to healthy cells. It also contains a gene for a protein, NIS, which helps the body concentrate iodine making it possible to track where the virus goes. VSV-hIFNbeta-NIS may be able to kill tumor cells without damaging normal cells. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving VSV-hIFNbeta-NIS with ruxolitinib phosphate may work better in treating patients with endometrial cancer compared to VSV-hIFNbeta-NIS alone.
    Location: Mayo Clinic, Rochester, Minnesota

  • VSV-hIFNbeta-NIS with or without Ruxolitinib Phosphate in Treating Patients with Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma

    This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus carrying the human NIS and IFN beta genes (VSV-hIFNbeta-sodium iodide symporter [NIS]) with or without ruxolitinib phosphate in treating patients with multiple myeloma, acute myeloid leukemia, or T-cell lymphoma that has come back or does not respond to treatment. A virus, called VSV-hIFNbeta-NIS, which has been changed in a certain way, may be able to kill cancer cells without damaging normal cells. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving VSV-hIFNbeta-NIS and ruxolitinib phosphate may work better at treating multiple myeloma, acute myeloid leukemia and T-cell lymphoma.
    Location: Mayo Clinic, Rochester, Minnesota

  • Ruxolitinib Phosphate and Chemotherapy Given before and after Reduced Intensity Donor Stem Cell Transplant in Treating Patients with Myelofibrosis

    This pilot clinical trial studies the side effects and best dose of ruxolitinib phosphate when given together with chemotherapy before and after a donor stem cell transplant in treating patients with myelofibrosis. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fludarabine phosphate and melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ruxolitinib phosphate together with chemotherapy before and after a donor stem cell transplant may help stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient’s immune cells and help destroy any remaining cancer cells.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California

  • Ruxolitinib Phosphate and Bortezomib in Treating Patients with Relapsed or Refractory Lymphoma

    This phase I trial studies the side effects and best dose of ruxolitinib phosphate and bortezomib in treating patients with relapsed or refractory lymphoma. Ruxolitinib phosphate and bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

  • Ruxolitinib Phosphate or Dasatinib with Chemotherapy in Treating Patients with Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

    This phase II trial studies the side effects and best dose of ruxolitinib phosphate and how well it works compared to dasatinib when given with chemotherapy in treating patients with Philadelphia chromosome-like acute lymphoblastic leukemia that has come back or has not responded to treatment. Ruxolitinib phosphate and dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving ruxolitinib phosphate or dasatinib with chemotherapy works better in treating patients with previously treated acute lymphoblastic leukemia.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Ruxolitinib Phosphate and Azacytidine in Treating Patients with Myelofibrosis or Myelodysplastic Syndrome / Myeloproliferative Neoplasm

    This phase II trial studies how well ruxolitinib phosphate and azacytidine work in treating patients with myelofibrosis or myelodysplastic syndrome / myeloproliferative neoplasm. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacytidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ruxolitinib phosphate and azacytidine may be an effective treatment for myelofibrosis or myelodysplastic syndrome / myeloproliferative neoplasm.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Pembrolizumab and Ruxolitinib Phosphate in Treating Patients with Metastatic Stage IV Triple Negative Breast Cancer

    This phase I trial studies the side effects and best dose of ruxolitinib phosphate when given together with pembrolizumab in treating patients with stage IV triple negative breast cancer that has spread to other places in the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and ruxolitinib phosphate together may work better in treating patients with stage IV triple negative breast cancer.
    Location: Mayo Clinic in Arizona, Scottsdale, Arizona

  • Ruxolitinib Phosphate and Nilotinib in Treating Patients with Chronic Phase Chronic Myelogenous Leukemia Who Have Received Tyrosine Kinase Inhibitor Therapy and Achieved a Major Molecular Remission

    This phase I / II trial studies the side effects and best dose of ruxolitinib phosphate when given together with nilotinib and to see how well they work in treating patients with chronic phase chronic myelogenous leukemia that is under good, but not perfect control on tyrosine kinase inhibitor therapy. Ruxolitinib phosphate and nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations